Navigation Links
EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
Date:11/7/2008

ROCKVILLE, Md., Nov. 7 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company update at the Rodman and Renshaw 10th Annual Healthcare Conference, which is being held November 10-12, 2008 at the New York Palace Hotel in New York, NY. Mr. Burns' presentation is scheduled for Tuesday, November 11, 2008 at 2:25 p.m. (local time).

Mr. Burns' presentation will be web cast and, as previously announced, will serve as the Company's third quarter 2008 update. The presentation can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director

Corporate Communications &

Investor Relations

EntreMed, Inc.

240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
9. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
10. EntreMed Reports First Quarter 2008 Financial Results
11. EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... ... “When the Stars Lead Home”: a poignant story of loss, determination, and perseverance. ... an avid reader who lives in the Pacific Northwest with her husband, daughter, two ... Camp. She couldn’t be more grateful. , Twelve-year old Tizzy could not believe how ...
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring ... School District had left education officials with a number of critical issues to address ... flooring had to be accomplished with little or no disruption to class schedules. Second, ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... medical image management and interpretation, has received U.S. Food and Drug Administration (FDA) ... is a web-based, scalable and secure cloud platform for medical image management. At ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Myers Jackson is ... has the ability to sell luxury homes anywhere on the planet. The luxury home ... side from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill Auction ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... If you are thinking of a visit ... interested in business architecture, October is the perfect time to visit. , Business Architecture Associates ... à la carte offering for individuals, as a 4-½ day package for individuals, and as ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)... Calif. , May 23, 2017  Leaf ... most innovative medical devices for pressure ulcer prevention, ... the American Association of Critical Care Nurses, National ... May 22-25. The Leaf Patient Monitoring ... specifically for the hospital environment.  The system seamlessly ...
(Date:5/18/2017)... , May 17, 2017  Bayer announced today that ... will be presented at the 53 rd Annual ... taking place June 2-6 in Chicago ... ASCO span prostate, colorectal, liver and thyroid cancers, as ... the Phase II CHRONOS-1 trial of copanlisib in patients ...
(Date:5/11/2017)...  Thornhill Research Inc. ( Toronto, Ontario, ... USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the U.S. ... (CCC) ( Ottawa, Ontario, Canada ) ... anesthesia to patients requiring emergency medical procedures in ... Corps have been a longtime partner with Thornhill ...
Breaking Medicine Technology: